Mankind Pharma Ltd (MANKIND) — Capital Reinvestment Ratio

Latest as of September 2025: 0.17x

Mankind Pharma Ltd (MANKIND) has a Capital Reinvestment Ratio of 0.17x as of September 2025, meaning it reinvests 0% of its operating cash flow (Rs16.37 Billion) in capital expenditures (Rs2.71 Billion). Check tangible equity quality of Mankind Pharma Ltd to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.17x
Capex / Operating Cash Flow

Operating Cash Flow

Rs16.37 Billion
INR

Capital Expenditures

Rs2.71 Billion
INR

Data as of

Sep 2025
Most recent filing

Mankind Pharma Ltd Capital Reinvestment Ratio (2019–2026)

This chart tracks Mankind Pharma Ltd's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see MANKIND cash flow conversion.

Annual Capital Reinvestment Ratio for Mankind Pharma Ltd (2019–2026)

Year-by-year Capital Reinvestment Ratio for Mankind Pharma Ltd from 2019 to 2026. See MANKIND free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (INR) Capital Expenditures YoY Change
2026 0.25x Rs25.16 Billion Rs6.26 Billion ▲ +30.3%
2025 0.19x Rs24.13 Billion Rs4.61 Billion ▲ +7.5%
2024 0.18x Rs21.52 Billion Rs3.82 Billion ▼ -61.3%
2023 0.46x Rs18.13 Billion Rs8.32 Billion ▼ -82.0%
2022 2.55x Rs9.20 Billion Rs23.46 Billion ▲ +828.6%
2021 0.27x Rs11.37 Billion Rs3.12 Billion ▲ +28.9%
2020 0.21x Rs10.70 Billion Rs2.28 Billion ▼ -57.0%
2019 0.50x Rs6.00 Billion Rs2.98 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow